ABBOTT ULTANE INHALATION ANESTHETIC SHIPMENTS TO BEGIN BY END OF JUNE; PHASE IV NEPHROTOXICITY STUDIES TO FOCUS ON COMPOUND A, LOW GAS FLOW RATES
Executive Summary
Abbott will begin shipping the inhaled anesthetic Ultane (sevoflurane) by the end of June, the company indicated following FDA approval of the drug June 7 for induction and maintenance of general anesthesia in adult and pediatric patients undergoing inpatient and outpatient surgery.